Jove
Visualize
Contáctanos
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Videos de Conceptos Relacionados

Peptic Ulcer Disease I: Introduction01:30

Peptic Ulcer Disease I: Introduction

962
Peptic Ulcer Disease (PUD) is characterized by mucosal excavation in the esophagus, stomach, pylorus, or duodenum. It can manifest as acute or chronic based on the extent and duration of mucosal involvement.
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
962
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors01:24

Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors

1.4K
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI)  tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
1.4K
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

593
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
593
Peptic Ulcer Disease II: Pathophysiology01:28

Peptic Ulcer Disease II: Pathophysiology

2.4K
Peptic Ulcer Disease (PUD) is characterized by the development of ulcers in the stomach or duodenal mucosa. Its pathophysiology is complex, involving a balance between damaging and protective elements.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
2.4K
Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies01:28

Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies

728
Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
728
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors01:13

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors

1.1K
Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
1.1K

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

Long-Term Colorectal Cancer Incidence After Adenoma and Serrated Polyp Removal: Results From the Colonprev Trial.

United European gastroenterology journal·2026
Same author

Colonoscopy versus biennial FIT screening: a post hoc sustained-strategy analysis of the COLONPREV Trial.

Gut·2026
Same author

Waiting for cholecystectomy: determinants of prioritization for delayed cholecystectomy in a universal public healthcare system-post hoc analysis of RELAPSTONE cohort (WAIT-CHOL study).

BJS open·2026
Same author

Validation of Predictive Equations for Estimating Lean Soft Tissue and Fat-Free Mass in Class II-V Obesity: A Multicenter Observational Study with Implications for Bariatric Surgery Monitoring.

Journal of obesity & metabolic syndrome·2026
Same author

Editorial: Advancing gastrointestinal disease diagnosis with interpretable AI and edge computing for enhanced patient care.

Frontiers in medicine·2026
Same author

Higher Doses of Bismuth and Antibiotics Do Not Improve Helicobacter pylori Treatment Effectiveness: Results From the European Registry on Helicobacter pylori Management.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2026
Same journal

Assisted dying and the silencing of medicine's next generation.

Lancet (London, England)·2026
Same journal

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Lancet (London, England)·2026
Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026
Same journal

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026
Same journal

Research priorities for characterising Bundibugyo virus.

Lancet (London, England)·2026
Same journal

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Lancet (London, England)·2026
Ver todos los artículos relacionados

Video Experimental Relacionado

Updated: Mar 7, 2026

Author Spotlight: Advancing Early Detection and Treatment of Gastrointestinal Tumors
03:05

Author Spotlight: Advancing Early Detection and Treatment of Gastrointestinal Tumors

Published on: February 16, 2024

1.6K

Enfermedad de la úlcera péptica

Angel Lanas1, Francis K L Chan2

  • 1Service of Digestive Diseases, University Clinic Hospital Lozano Blesa, University of Zaragoza, IIS Aragón, CIBEREHD, Zaragoza, Spain.

Lancet (London, England)
|March 1, 2017
PubMed
Resumen
Este resumen es generado por máquina.

La enfermedad de úlcera péptica es menos común pero más difícil de tratar debido a la resistencia a los antimicrobianos y a las terapias complejas. Nuevos desafíos surgen de las úlceras no relacionadas con H. pylori o AINE, que requieren estrategias de manejo actualizadas.

Más Videos Relacionados

Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance
05:23

Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance

Published on: March 7, 2025

873
The Dyspepsia Educational Tool As a Novel Aid in Dyspepsia Management
06:40

The Dyspepsia Educational Tool As a Novel Aid in Dyspepsia Management

Published on: June 29, 2019

7.1K

Videos de Experimentos Relacionados

Last Updated: Mar 7, 2026

Author Spotlight: Advancing Early Detection and Treatment of Gastrointestinal Tumors
03:05

Author Spotlight: Advancing Early Detection and Treatment of Gastrointestinal Tumors

Published on: February 16, 2024

1.6K
Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance
05:23

Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance

Published on: March 7, 2025

873
The Dyspepsia Educational Tool As a Novel Aid in Dyspepsia Management
06:40

The Dyspepsia Educational Tool As a Novel Aid in Dyspepsia Management

Published on: June 29, 2019

7.1K

Área de la Ciencia:

  • Gastroenterología
  • Médico interno
  • Farmacología

Sus antecedentes:

  • La prevalencia de la úlcera péptica ha disminuido debido a la reducción de las tasas de infección por Helicobacter pylori y al aumento del uso de inhibidores de la bomba de protones.
  • Sin embargo, el manejo de la PUD es cada vez más complejo, impulsado por el aumento de la resistencia a los antimicrobianos y el uso generalizado de terapias antitrombóticas en poblaciones que envejecen.
  • Un número creciente de úlceras no relacionadas con H. pylori o AINE presentan desafíos diagnósticos y terapéuticos únicos.

Objetivo del estudio:

  • Proporcionar una visión global de los conocimientos actuales y los avances recientes en la enfermedad de la úlcera péptica.
  • Discutir las directrices actualizadas para el manejo de la infección por H. pylori y el tratamiento de las complicaciones de PUD.
  • Resaltar las necesidades no cubiertas en el diagnóstico y tratamiento de casos complejos de úlcera péptica.

Principales métodos:

  • Revisión de la literatura reciente sobre la patogénesis y la epidemiología de las úlceras pépticas.
  • Análisis de las directrices clínicas actuales para la erradicación de H. pylori y el tratamiento de la PUD.
  • Discusión de estrategias terapéuticas para la DPU asociada con agentes antitrombóticos y AINE.
  • Identificación de las lagunas de conocimiento y direcciones de investigación futuras.

Principales resultados:

  • Disminución de la prevalencia de la PUD asociada con H. pylori.
  • Aumento de los desafíos en el manejo de la PUD debido a la resistencia a los antimicrobianos y el uso de medicamentos antitrombóticos.
  • La aparición de úlceras no causadas por H. pylori y no AINE es un problema clínico significativo.
  • Necesidad de enfoques terapéuticos actualizados y nuevas investigaciones.

Conclusiones:

  • El tratamiento de la úlcera péptica requiere adaptación a la evolución de las tendencias epidemiológicas y a los retos terapéuticos.
  • Es fundamental abordar la resistencia a los antimicrobianos y optimizar el tratamiento en pacientes en tratamiento antitrombótico.
  • Se necesita más investigación para comprender y manejar eficazmente las úlceras pépticas complejas.